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IN RECENT YEARS, many studies have
examined the immune reactivity of cancer
patients. A variety of tests, including
recall and de novo antigen skin testing,
have been used to assess immune function
in these patients. The relationship of
skin reactivity to tumour histology, the
stage ofthedisease, prognosis and immuno-
therapeutical success or failure (Bates
et al., 1979; Jassem & Serkies, 1980;
Krown et al., 1980; Lang et al., 1980;
Rasmussen et al., 1980; Wanebo et al.,
1980) is still hotly debated.
In recent decades all children in
Czechoslovakia have been vaccinated with
BCG (Bacillus Calmette-Guerin) in their
first week of life. Their delayed cutaneous
hypersensitivity reactions to tuberculin
were followed serially in specialized
"Calmettization" centres. The Monrad
contact test (with Unguentum tuberculini
sec. Monrad) was applied at the age of
6 months, and, ifnegative, repeated at the
age of 1 year. A classical Mantoux test
(with PPD-RT 23 State Serum Institute,
Copenhagen in 0.05%0 Tween 80) was
carried out at the ages of 6 and 12 years.
[This test was performed with 2 TU
(0.04 ,ug of tuberculin purified protein
derivativein 0 I ml), aninduration > 5 mm
being considered positive.] All this was
done in order to revaccinate repeatedly
anergic children, or to examine extreme
responders with respect to tuberculosis.
Nevertheless careful registers of these
reactions also make it possible to evaluate
the reactivity of children years later.
The aim of the present study was to
see whether there were any abnormalities
in skin response to tuberculin in children
who subsequently developed manifest
malignant disease. For this purpose
"Calmettization" records of patients with
different malignant diseases were com-
pared with records of other children of
similar age.
The malignancy group was represented
by 189 children (108 boys and 81 girls)
who had been treated in the years 1972-
1977 in various departments of the
University Hospital, Brno. Tumours were
histologically confirmed in all cases. The
brief outline of the types of malignancies
and number of cases is as follows: leuk-
aemia (mostly acute lymphoblastic)-46,
Hodgkin's lymphoma 10, non-Hodgkin's
lymphoma-7, Wilms' tumour-22, neuro-
blastoma 1.2, retinoblastoma 23, brain
tumour 34, sarcoma of various origins-
13, teratoma and germinoma 6, miscel-
laneous-16. The mean age at which
clinical diagnosis was established was
5.53 years, with a range of 6 months-
15 years. All children were divided into
groups according to age: under 1 year,
1-5 years, 6-10 years and 11-1.5 years.
"Calmettization" records ofanother 400
children chosen at random (100 children,
50 boys and 50 girls, in each of the above-
mentioned age categories) were taken as
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TABLE.-The distribution of +ve and -ve tuberculin tests in children up to 5 years of age
A-allpatients; B-separate considerationfor "solid" tumours and lymphoproliferative
neoplasms; 1-all patients and tests; 2-tests<1 year before diagnosis (patients) or
presentation (controls); 3-tests > 1 year before diagnosis (patients) or presentation
(controls). AllX2 orP tests refertocomparison with Controls. Onlyone (italics) issignificant
A
t ~~~A_
+ve -ve total
1 Cancer 103 13 116
Controls 171 29 200
2 Cancer 30 6 36
Controls 85 24 109
3 Cancer 73 7 80
Controls 86 5 91
B
x2
"Solid" tumours
0- 691 Lymphoproliferative
neoplasms
"Solid" tumours
0 472 Lymphoproliferative
neoplasms
"Solid" tumours
0* 691 Lymphoproliferative
neoplasms
+ ve -ve total
70 12 82
33 1 34
x2 or P test
( *025
0. 044*
25 5 30 0 148
5 1 6 0.612*
45 7 52 20-(19
28 0 28 0 255*
controls. There were no differences in skin
reactivity between boys and girls, so
sex was ignored in evaluating the results.
Because all malignant diseasesarereported
and recorded in a central oncological
register, it was possible to ascertain that
no malignant disease was present in the
controls.
In comparing the data, only 2 types of
reaction (positive and negative) were
recognized. The occurrence of positivity
and negativity in every age group of
patients with malignancies was compared
with the same data in the corresponding
control group. Particular attention was
paid to possible changes in reactivity
shortly before the illness. Intervals be-
tween testing and diagnosing the disease
were therefore also taken into account.
Attention was paid also to the type of
neoplasm, especially with the aim of
detecting any differences in reactivity in
the lymphoproliferative malignancies.
An example of evaluation is demon-
strated intheTable. Thestatistical evalua-
tion was carried out by x2 test and/or
Fisher's P test (=direct) calculation of
probability. The results of the 2 youngest
agegroups children under 1 year and those
1-5 years of age, are treated jointly (A1).
The subdivision was made according to
whetherthetestingwas carriedoutwithin 1
year (A2) or more (A3) ofdiagnosing malig-
nancy. Accepting that the testing was
performed at the age of 6 months (and
only these results are here presented) the
children in A2 had malignancy ascer-
tained at an age under 18 months, and
children in A3 had the diagnosis proved
later, between the age of 18 months and
5 years. Differentiation between "solid"
tumours and lymphoproliferative neo-
plasms was also made (the B subdivision
is the same as in A). The distribution of
positive and negative results was similar
in all compared groups; substantial differ-
ences were never found. In the comparison
between lymphoproliferative neoplasms
and controls, B1 slightly exceeds the
limit of significance (P< 0 05); the fre-
quency of positive results in patients was
greater than in controls. This not very
convincing significance did not arise if
the group was divided into 2 age groups
(under 1 year and 1-5 years) or sub-
divided according to interval between
testing and diagnosing. This result never-
theless convincingly demonstrates that
cutaneous reactivity before diagnosis of
leukaemia or lymphoma is quite good. In
the same manner, all comparisons were
analysed in detail, with the same results.
From these results we can conclude that
the capability for tuberculin immune
response and the immunological memory
for this antigen preceding the appearance
of maligant disease in children do not
differ from those in normal children. Our
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results show that this reactivity was not
abnormal, even within the short period
before diagnosis. We must suppose that
theimpairmentofdelayedhypersensitivity
found in advanced stages of malignant
disease is rather the result of the grave
illness.
We thank Pavia Petrova for her help with evalua-
tion of the "Calmettization" records.
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